Neurosciences

Cell therapy and molecular physiology

Juan José Toledo Aral
Juan José Toledo Aral
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratory: 102

Juan José Toledo Aral

Back to program
  1. Group members
  2. Research areas
  3. Publications
  4. News

Group: Cell therapy and molecular physiology

Directory
Group members Cell therapy and molecular physiology
  • Amil Pérez, Benito.MD/PhD - Pediatrics ("Sagrado Corazón" Hospital). Research collaborator.
  • Cala Fernández , Fernando.Técnico de Apoyo
  • Galán Cobo, Ana.Degree in Biology. PhD student.
  • García Swinburn, Roberto.Ldo. Bioquímica. Predoctoral.
  • Hurtado Álvarez, Lidia.Doctora en Biología
  • Muñoz Lombardo, Enrique.Técnico de Apoyo
  • Olivares Blanco, Magdalena.Degree in Medicine & Surgery. Resident-Neurology (HUVR).
  • Ramírez Lorca, Reposo.Doctora en Farmacia
  • Suárez Luna, Mª Nela.Degree in Biology. Technician.
  • Toledo Aral, Juan José.MD/PhD. Professor/Associate Researcher (University of Seville/HUVR).
  • Vidal Blandino, Marisa.Degree in Medicine. Nephrologist.
  • Villadiego Luque, Fco. Javier.PhD in Biology. Post-doctoral fellow

Research areas

Cell therapy.

This group carries out research on the use of cell therapy in neurodegenerative diseases. The main objective of this line of work is to study the beneficial effects of carotid body transplants in animal models of Parkinson's disease. Different models of Parkinson's disease in rats and mice are used, and a range of cell types have been tested. An important aspect of this area is the study of the trophic action of transplants, and of the trophic factors implicated. The group also participates in studies with patients aimed at possible clinical applications of discoveries made in the laboratory. To this extent, the group maintains close collaborative links with other IBIS groups.

Aquaporins.

The group also maintains a line of research aimed at exploring the physiology of aquaporins, from the study of their molecular characteristics and the regulation of their genetic expression, to possible novel functions of these membrane proteins, with particular emphasis on their role in different pathologies. Specifically, the regulation by hypoxia of the genetic expression of aquaporins, and the role these proteins play as gas channels are under investigation. Concerning the latter, the physiopathological role of different aquaporins in pulmonary diseases and tumor processes is being studied. In relation to this research line, which is being led by Dr. Echevarría, collaborations with other IBIS groups and various clinical services within HUVR have been established.

News

RETOS-COLABORACIÓN 2015 – TOLEDO ARAL, JUAN JOSÉ RTC-2015-3309-1 financiado por MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD

gobierno-espana-ministerio-economia-y-competitividad-ue

Título: “Desarrollo de una terapia para el tratamiento de variantes genéticas de α-sinucleína en la enfermedad de Parkinson”

El objetivo de este proyecto es el desarrollo de una terapia basada en el compuesto NLF-PD-1233 (de nLife), dirigido a los pacientes con enfermedad de Parkinson que presentan alteraciones en la expresión del gen de la alfa-sinucleína.

La selección de pacientes en función de sus variantes génicas permitirá normalizar la población en estudio y obtener una mayor fortaleza en los estudios de identificación de nuevos biomarcadores.

Para la búsqueda de biomarcadores se evaluará la eficacia del tratamiento con NLF-PD-1233 en un modelo in-vitro de progresión de la enfermedad en células IPCs de pacientes que presentan estas alteraciones del gen SNCA. Por otra parte, el consorcio estudiará biomarcadores subrogados al tratamiento con NLF-PD-1233 asociados a neuroinflamación, neurodegeneración, medidas de viabilidad celular, función neuronal, microPET y estudios de comportamiento, en modelos in-vitro, in-vivo y en un modelo de administración crónica de MPTP en ratones transgénicos que presentan duplicación o triplicación del gen SNCA y las mutaciones puntuales del SNCA más abundantes.